Buspirone has not been proven safe or unsafe during pregnancy because no well-controlled studies have been done in pregnant people. Animal studies at doses roughly 30 times the maximum human dose showed no fertility problems or fetal damage, which led the FDA to previously classify it as Pregnancy Category B. That’s a relatively reassuring category, but it reflects a gap in human data rather than confirmed safety.
What the Human Evidence Shows
The most relevant human data comes from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications, which tracked pregnancy outcomes after first-trimester buspirone exposure. Among the women enrolled, no congenital malformations were identified in infants exposed to buspirone during early pregnancy. That’s encouraging, but the sample size was small, so it can’t rule out rare risks the way a study of thousands of pregnancies could.
Animal research offers a bit more detail. In rat studies, buspirone given during pregnancy did not cause significant changes in the body weight of newborn pups, unlike fluoxetine (a common SSRI), which was associated with a slight decrease in newborn weight. No increases in pregnancy length problems or pup deaths were linked to buspirone specifically. These findings are consistent with the FDA’s original assessment but, as with all animal data, don’t translate perfectly to humans.
How It Compares to SSRIs
SSRIs like sertraline and fluoxetine are the most commonly prescribed medications for anxiety and depression during pregnancy, and they have a much larger body of human research behind them. That larger evidence base is a double-edged sword: it means we know more about their risks (including a small chance of neonatal adaptation syndrome and, in some studies, modest increases in certain birth complications), but it also means clinicians feel more confident managing those risks.
Buspirone’s smaller evidence base makes it harder for providers to weigh risks and benefits with the same precision. It is not typically a first-line recommendation for anxiety during pregnancy, largely because of this data gap rather than because of known harms. If you’re already taking buspirone and become pregnant, that’s a different conversation than starting it for the first time while pregnant.
Risks of Untreated Anxiety During Pregnancy
The safety question isn’t just about the medication. Untreated anxiety during pregnancy carries its own set of risks that matter for both you and the baby. Even subclinical anxiety symptoms, meaning symptoms that fall short of a formal diagnosis, have been linked to restricted fetal growth and preterm birth. Chronic stress suppresses the immune system, making pregnant people more susceptible to infections. Maternal anxiety has also been connected to emotional regulation difficulties and neurological changes in offspring after birth.
This is why the decision is rarely as simple as “stop the medication to be safe.” For some people, the risks of going untreated are greater than the theoretical risks of a medication with a reassuring (if limited) safety profile. Your provider will weigh the severity of your anxiety, how well you respond to buspirone specifically, and whether non-medication options like therapy could bridge the gap.
Buspirone and Breastfeeding
If you’re also thinking ahead to breastfeeding, the data here is more concrete. A study of nine women taking buspirone twice daily (at doses ranging from 7.5 to 30 mg) found that buspirone itself was undetectable in breast milk. An active metabolite was present in all samples, but the estimated relative infant dose averaged just 0.91%, with a range of 0.21% to 2.17%. Anything under 10% is generally considered compatible with breastfeeding, so buspirone falls well within that threshold. The FDA labeling still advises caution, noting that excretion in human milk hasn’t been fully characterized, but the available numbers are reassuring.
What This Means Practically
Buspirone sits in a gray zone: no red flags in animal or limited human studies, but not enough data to call it definitively safe. If you’re currently taking buspirone and planning a pregnancy or already pregnant, the key factors to discuss with your provider include how severe your anxiety is, whether you’ve tried other treatments, and whether stopping the medication could lead to a relapse that poses its own risks to the pregnancy. Abruptly stopping any psychiatric medication during pregnancy can itself be destabilizing, so any changes should be gradual and supervised.
For people whose anxiety is well-managed on buspirone and who haven’t responded well to other options, continuing it may be the most reasonable choice. For those with milder symptoms, a switch to a better-studied medication or a trial of cognitive behavioral therapy might offer more certainty. There is no one-size-fits-all answer, but the existing evidence leans toward cautious reassurance rather than alarm.